Chief Medical Officer and Head of Development at Denali Therapeutics Carole Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics in San Francisco, CA. Denali Therapeutics is dedicated to therapeutic discovery and development of treatments for neurodegenerative diseases. Previously, Dr. Ho served as Vice President of Early Clinical Development at Genentech, where she headed the early clinical development for all indications outside of oncology, including neurology, ophthalmology, immunology, and infectious disease. She served as Group Medical Director of Rheumatology and Group Medical Director of Personalized Health Care for Inflammatory diseases. Prior to Genentech, she held a faculty appointment in the Department of Neurology at Stanford University and was subsequently a Medical Director at Johnson and Johnson.